GERMANTOWN, Md., March 13,
2025 /PRNewswire/ -- Precigen,
Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing
in the development of innovative gene and cell therapies to improve
the lives of patients, today announced the Company will release
full year 2024 financial results and provide business updates on
Wednesday, March 19, 2025. The
Company will host a conference call to discuss results that day at
4:30 PM ET.
The conference call may be accessed by dialing 1-800-836-8184
(North America) or 1-646-357-8785
(International). Participants are asked to dial in 10-15 minutes in
advance of the scheduled call time to facilitate timely connection
to the call.
Event details can be found on Precigen's website in the Events
& Presentations section at
investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with
Precision®
Precigen (Nasdaq: PGEN) is a
dedicated discovery and clinical stage biopharmaceutical company
advancing the next generation of gene and cell therapies using
precision technology to target the most urgent and intractable
diseases in our core therapeutic areas of immuno-oncology,
autoimmune disorders, and infectious diseases. Our technologies
enable us to find innovative solutions for affordable
biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline
of well-differentiated therapies toward clinical proof-of-concept
and commercialization. For more information about Precigen, visit
www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements
are based upon the Company's current expectations and projections
about future events and generally relate to plans, objectives, and
expectations for the development of the Company's business,
including the timing and progress of preclinical studies, clinical
trials, discovery programs and related milestones, the promise of
the Company's portfolio of therapies, and in particular its CAR-T
and AdenoVerse therapies. Although management believes that the
plans and objectives reflected in or suggested by these
forward-looking statements are reasonable, all forward-looking
statements involve risks and uncertainties and actual future
results may be materially different from the plans, objectives and
expectations expressed in this press release. The Company has no
obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. For further information on potential risks
and uncertainties, and other important factors, any of which could
cause the Company's actual results to differ from those contained
in the forward-looking statements, see the section entitled "Risk
Factors" in the Company's most recent Annual Report on Form 10-K
and subsequent reports filed with the Securities and Exchange
Commission.
Investor Contact:
Steven M.
Harasym
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M.
Gregory
press@precigen.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-to-announce-full-year-2024-financial-results-and-provide-business-updates-on-march-19th-302400648.html
SOURCE Precigen, Inc.
